Eli Lilly fires back at The New York Times after the paper ran two unfavorable stories about the company's lucrative Schizophrenia drug, Zyprexa. Mike Huckman, CNBC Pharmaceuticals Reporter, has the details.
Topics:
Media | Pharmaceuticals | Biotechnology | Stock Market
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT